Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5496370 | 0.98 | PARP1 (0.45) | PARP1ADORA2APTPRCBRD4TNF | |
| SCHEMBL4230483 | 0.78 | CDK5 (0.49) | PARP1KMT2ATYRPIM1CSNK1A1 | |
| SCHEMBL307690 | 0.78 | TYMS (0.39) | TYMSPIM1CSNK1A1DYRK1A | |
| SCHEMBL9194801 | 0.78 | PARP1 (0.46) | PARP1ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL831827 | 0.78 | PARP1 (0.46) | PARP1TNFCRBNALDH1A1MEN1 | |
| SCHEMBL4009918 | 0.75 | MEN1 (0.43) | L3MBTL1ALDH1A1MEN1POLBMAPT | |
| SCHEMBL4860239 | 0.75 | — | — | |
| SCHEMBL9194546 | 0.73 | S100A4 (0.46) | PTPRCALDH1A1MEN1CYP1A2POLB | |
| SCHEMBL1261840 | 0.70 | PARP1 (0.42) | PARP1ADORA2APTPRCBRD4TNF | |
| SCHEMBL9980468 | 0.70 | MAPT (0.41) | L3MBTL1ALDH1A1MEN1RGS12CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180042919-A1 | PARP Inhibitors for the Treatment of Major Depressive Disorder and Related Conditions | EAST TENNESSEE STATE UNIVERSITY RESEARCH FOUNDATION | 2018-02-15 | — | — | US | claimed |
| US-20120022026-A1 | METHOD OF TREATING CANCER | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2012-01-26 | — | — | US | claimed |
| EP-2387403-A1 | METHOD OF TREATING CANCER | Academisch Medisch Centrum bij de Universiteit van Amsterdam (NL) | 2011-11-23 | — | — | EP | claimed |
| US-20110253692-A1 | Electrical heater for vehicle windshields and windows | SCHAUBLE RICHARD EGON | 2011-10-20 | — | — | US | claimed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | claimed |
| WO-2010082813-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | claimed |
| WO-2001022960-A1 | TREATMENT OF CARBON MONOXIDE POISONING | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY DOING BUSINESS AS CAROLINAS MEDICAL CENTER (US) | 2001-04-05 | — | — | WO | claimed |
| US-20250381221-A1 | Compositions and Methods for Treating Cancer | IN8BIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-25 | — | — | US | disclosed |
| EP-4376822-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | Lantern Pharma Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-1407034-A2 | RECOMBINATION SYSTEMS AND A METHOD FOR REMOVING NUCLEIC ACID SEQUENCES FROM THE GENOME OF EUKARYOTIC ORGANISMS | Sungene GmbH & Co. KgAA (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004017749-A2 | USE OF ASTAXANTHIN-CONTAINING PLANTS OR PARTS OF PLANTS OF THE GENUS TAGETES AS ANIMAL FEED | SUNGENE GMBH & CO. KGAA (DE) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018693-A2 | METHOD FOR THE PRODUCTION OF KETOCAROTINOIDS IN FLOWER PETALS ON PLANTS | SUNGENE GMBH & CO.KGAA (DE) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018688-A1 | METHOD FOR THE PRODUCTION OF $G(B)-CAROTINOIDS | SUNGENE GMBH & CO. KGAA (DE) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003004659-A2 | RECOMBINATION SYSTEMS AND A METHOD FOR REMOVING NUCLEIC ACID SEQUENCES FROM THE GENOME OF EUKARYOTIC ORGANISMS | SUNGENE GMBH & CO. KGAA (DE) | 2003-01-16 | — | — | WO | disclosed |
| WO-2001022960-A1 | TREATMENT OF CARBON MONOXIDE POISONING | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY DOING BUSINESS AS CAROLINAS MEDICAL CENTER (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001022960-A1 | TREATMENT OF CARBON MONOXIDE POISONING | CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY DOING BUSINESS AS CAROLINAS MEDICAL CENTER (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | PARP1 1/4885ADORA2A 4151/4885PTPRC 4673/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | PARP1 1/4885ADORA2A 3863/4885PTPRC 4673/4885 |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | PARP1 3/4885ADORA2A 3637/4885PTPRC 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.